FT.com health
Novartis: change at the top
Daniel Vasella’s departure could be the moment for an overdue check-up of the pharma group which faces losing $3.5bn in patented revenue this year
Categories: Health
Novartis chairman leaves mixed legacy
Healthcare group diversified under Daniel Vasella’s leadership, but criticism has been levelled at departing chairman over remuneration
Categories: Health
Vasella to step down as Novartis chairman
Veteran who led Swiss pharmaceuticals group for 17 years to be replaced by Reinhardt, who was overlooked for position of chief executive in 2010
Categories: Health
Allergan adds MAP to migraine plans
US maker of Botox pays a 60% premium for MAP Pharmaceuticals in a $958m deal to expand its offering of migraine headache treatments
Categories: Health
US healthcare costs seek home remedy
FT series: America’s Debt Dilemma – Richard McGregor on the battle to control the spiralling cost of Medicare, on which the US spent $550bn in 2012
Categories: Health
Dutch health system hopes fall short
Reforms replaced the Netherlands’ centralised system with a market-based one that resembles the US’s so-called ‘Obamacare’ changes
Categories: Health
J&J pledges growth for consumer business
US healthcare group reports strong earnings but announces an $800m charge for legal costs associated with recall of its metal-on-metal hip devices
Categories: Health
Universities back venture capital fund
Rock Spring Ventures has gathered an unusual pooled commitment of £6m from the endowments of Aberdeen, Glasgow and Edinburgh universities
Categories: Health
Care UK signals consolidation in sector
Deal is the second in less than six months for private-equity owned group amid a rise in the number of NHS-funded operations carried out by sector
Categories: Health
Advert for e-cigarettes to be shown on TV
Because the product does not contain tobacco, e-cigarette makers have begun sometimes tortuous marketing efforts to exploit a fast-growing market
Categories: Health
Pfizer’s Zoetis IPO set to raise $2.2bn
Filing with Securities and Exchange Commission suggests that pharmaceuticals group’s animal-health business could be valued at $12bn after spin-off
Categories: Health
Plasma Resources UK goes up for sale
Bids open Friday for blood plasma business following spin-off from NHS after government review, Germany’s Biotest has been cited as a potential bidder
Categories: Health
UnitedHealth faces uncertain times
Insurer’s stock likely to remain cheap until at least 2014 when US healthcare act is implemented and its full impact on future profits can be weighed
Categories: Health
The Bottom Line:If Mr Cable has his way...
"If Mr Cable had his way, all the big banks would be broken up and bonuses would be virtually eliminated - a sure-fire way in my view of guaranteeing an end to the UK’s ability to compete as an international financial centre. Let’s not forget that this is a man who is on record as saying that everyone who works in a bank has an ‘aristocratic lifestyle’ clearly demonstrating his lack of understanding of the sector." A tough line on bankers’ bonuses could make a brain drain of financial talent a distinct possibility, warns Paul Marsden. Read more